Company Description
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States.
It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery.
The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017.
RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
| Country | United States |
| Founded | 1997 |
| IPO Date | Jul 30, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 498 |
| CEO | Ronald Kurtz |
Contact Details
Address: 100 Columbia Aliso Viejo, California 92656 United States | |
| Phone | 949 521 7830 |
| Website | rxsight.com |
Stock Details
| Ticker Symbol | RXST |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001111485 |
| CUSIP Number | 78349D107 |
| ISIN Number | US78349D1072 |
| Employer ID | 94-3268801 |
| SIC Code | 3851 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ronald M. Kurtz M.D. | Co-President, Chief Executive Officer and Director |
| Eric J. Weinberg | Co-President and Chief Commercial Officer |
| Shelley B. Thunen | Co-President and Chief Financial Officer |
| Dr. Ilya Goldshleger Ph.D. | Co-President and Chief Operating Officer |
| Glebb Popov | Vice President of Finance and Accounting |
| Matt Haller Ph.D. | Chief Technology Officer |
| Oliver Moravcevic | Vice President of Investor Relations |
| Steve Everly | Senior Vice President of Sales of North America |
| Roy Freeman | Senior Vice President of Marketing and Professional Relations |
| Caroline Vaughn | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 15, 2025 | SCHEDULE 13G | Filing |
| Jul 8, 2025 | 8-K | Current Report |
| Jun 4, 2025 | 8-K | Current Report |
| May 20, 2025 | SD | Form - SD |
| May 7, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |
| Apr 21, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 21, 2025 | ARS/A | Filing |
| Apr 21, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 8, 2025 | SCHEDULE 13G | Filing |